Supplementary Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Authors :: Aung Naing
Luigi Manenti
Sabine Gutzwiller
Haiying Sun
Alexandros Xyrafas
Tyler A. Longmire
Catherine A. Sabatos-Peyton
Armando Santoro
Sofie Wilgenhof
F. Stephen Hodi
Chia-Chi Lin
Philippe L. Bedard
John Sarantopoulos
Patrick M. Forde
David Tai
Toshihiko Doi
Nicolas Mach
Hans Gelderblom
Giuseppe Curigliano
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Materials

Tools